ReviewDiagnostics (Basel, Switzerland)2022
Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Somatostatin Receptor Expression and Theranostic Applications Across Non-Neuroendocrine Tumors: A Molecular-to-Clinical Review.International journal of molecular sciences · 2026Review
- Novel Substituted Carboxamides as SSTR4 Agonists.ACS medicinal chemistry letters · 2026Article
- Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Imaging of Pineal Region Masses.Advances and technical standards in neurosurgery · 2026Review
- Diagnostic imaging and emerging image-guided neurointervention in brain tumors: a narrative review.Frontiers in radiology · 2026Review
- SSTR PET/CT for skull base low-grade meningioma: a critical tool for accurate gross tumor volume delineation in radiotherapy?Radiation oncology (London, England) · 2025Article
- "Rosary Sign" at Somatostatin Receptor PET in a Case of Recurrent Meningioma.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Clinical value of semi-quantitative parameters inEJNMMI reports · 2024Article
- Clinical value of semi-quantitative parameters inEJNMMI reports · 2024Article
- Postoperative [European journal of nuclear medicine and molecular imaging · 2023Article
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.European journal of nuclear medicine and molecular imaging · 2023Article
- Article
- Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives.International journal of molecular sciences · 2023Article
- Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT.Advances in radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aims of the present systematic review are to: (1) assess the diagnostic performance of somatostatin receptor (SSR)targeted positron emission tomography (PET) with different tracers and devices in patients affected by meningiomas; and (2) to evaluate the theranostic applications of peptide receptor radionuclide therapy (PRRT) in meningiomas. A systematic literature search according to PRISMA criteria was made by using two main databases. Only studies published from 2011 up to March 2022 in the English language with ≥10 enrolled patients were selected. Following our research strategy, 17 studies were included for the assessment. Fourteen studies encompassed 534 patients, harboring 733 meningiomas, submitted to SSR-targeted PET/CT (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.